Participated · Seed · Jul 2020

Terapet is developing a personalized quality‑assurance device for heavy ion (carbon ion) therapy to enable patient‑specific QA at carbon ion treatment centers. The company is working in a consortium with Yonsei University’s Heavy Ion Therapy Center and Oncosoft Inc. to deploy the device at Yonsei Cancer Center, South Korea’s first carbon ion therapy center. The collaboration officially begins on November 1, 2023 and will run for three years. Under a bilateral Innosuisse–KIAT program the partners have secured CHF 1,835,000 and KRW 1,500,000,000 dedicated to the project; the press release states all partners are fully funded. Terapet cites prior support from Venture Kick (including Venture Kick Stage 3 in 2020) and participation in Venture Leaders Life Sciences (2020); it was listed among TOP 100 Swiss Startups from 2021–2023. The company positions the work as enabling safer, more precise ion therapy treatments, particularly for critical tumour types and pediatric patients. Terapet is a Geneva-based Swiss MedTech company developing next-generation nuclear imaging technology. Its first product, Qualγscan, is a proton therapy quality‑assurance device designed to provide, for the first time, real‑time dose distribution assessment. The technology was developed in collaboration with CERN and Politecnico di Milano and will be validated with clinical partners at the Karolinska Institute and Skandion Clinic. Terapet announced a CHF 2.3M first closing of a Pre‑Series A round to commercialize Qualγscan and to fund R&D for additional nuclear imaging products. The company plans to use the funding to support marketing and sales for Qualγscan, including showcasing at PTCOG in Madrid, and to advance development of future in‑vivo, non‑invasive, 3D real‑time dose‑monitoring tools. The round was co‑led by EFI Lake Geneva Ventures and Nina Capital, with participation from existing shareholders Fongit, Venturekick and the founders; new board members from the lead investors have joined to support growth. Terapet develops technologies to make proton therapy more safe, precise and fast compared with conventional x‑ray radiotherapy. The company is building its first full-scale prototype for clinical validation. Terapet is partnering with world-class R&D partners including CERN, Karolinska Institute and Skandion Clinic to form two consortia. Those collaborations are funded through the Eurostars program and Innosuisse and will run for three years starting 01.02.2021. The Geneva-based startup has been awarded about CHF1,530,000 in non-dilutive funding to support prototype development and the consortia. Innosuisse has supported Terapet since project inception through training, coaching, mentoring and an initial Innovation Cheque for the CERN collaboration. Terapet develops a medical device that monitors proton dose delivery in vivo, non-invasively, in 3D and in real time, addressing uncertainty in current protontherapy treatment plans that rely on simulations. The system aims to ensure each patient receives the correct proton dose precisely localized, reducing margins around tumors and limiting damage to healthy tissue. By enabling dose verification during treatment, Terapet says providers can treat more patients and more types of cancer, while saving time and cost during therapy. The device is designed for minimal integration cost across different proton therapy centers. The company cites a current addressable market of CHF 750 million with projected growth to CHF 3 billion by 2030. Terapet plans to continue prototype development, expand R&D activities, and grow its team using recent funding. Terapet SA is developing a novel medical device that enables doctors to monitor delivered proton dose inside patients in‑vivo, non‑invasively, in 3D and in real time. The technology aims to make proton therapy safer, more precise and time‑saving, addressing challenges particularly important for children and tumours near critical organs. Terapet says its solution can ensure every patient receives the right dose and could help make proton therapy more affordable and accessible. The company has raised an oversubscribed CHF1 million seed financing to advance the technology and prepare it for clinical validation. Proceeds will fund development of Terapet’s first full‑scale prototype with support from CERN. Terapet plans to pursue clinical validation with clinical partner The Skandion Clinic in Sweden. Christina Vallgren is CEO.

Participated · Seed · Mar 2018

Kejako SA is a Genève-based startup developing minimally invasive surgical and non-invasive laser treatments to address presbyopia by targeting the root cause rather than providing static optical correction. The company has built a proprietary full-eye 3D parametric model combined with multi-physics numerical modeling to compute the eye’s optical and mechanical behavior and simulate disease impacts. That model is already calibrated for visual accommodation analysis and presbyopia simulation and is used to optimize patient-specific treatments and customize procedures. Kejako’s non-invasive approach applies specific spatial patterns and tailored laser energy settings to induce optical and mechanical changes in the lens, aiming to restore dynamic visual accommodation without inducing cataracts. Other applications of the parametric eye model are underway. The startup will use the new funding to accelerate development of its technology.

Participated · Equity · Apr 2012

Abionic develops and commercializes the abioSCOPE, a nanotechnology rapid diagnostic platform for clinical laboratories and point-of-care use. The system uses a single drop of blood and supports tests for allergies, iron deficiency, and a pancreatic stone protein (PSP) sepsis test that provides an indication within five minutes. The company has obtained FDA registration for its first rapid allergy tests in the United States. Proceeds from the financing will be used to expand its point-of-care IVD test portfolio for critical care and emergency medicine. Abionic is launching a multinational sepsis impact study beginning April 2018 to evaluate the PSP test in over 300 patients across 14 ICU sites in Switzerland, Italy, France, and the UK. Founded in 2010 and based at the Biopôle in Lausanne, Abionic is positioning its rapid tests for earlier sepsis detection and emergency-department risk stratification. Abionic is a medical device startup based in Lausanne, Switzerland, founded in 2010 as a spinoff from EPFL. It develops abioSCOPE, a point-of-care diagnostic tool that provides patients with personal allergy profiles. The system mixes a patient’s blood sample with a proprietary reagent and places it into a test capsule containing multiple biosensors capable of detecting a specific range of allergies. abioSCOPE tests are designed to complement skin tests by offering specific, quantitative and personalized serological in vitro allergy analysis at the point of care. The company closed a CHF3.8M Series B financing round to support regulatory and commercialization efforts. Abionic intends to use the funds to obtain FDA 510(k) certification and to begin commercialization in 2015, and added Martine Reindle and Urs Amstutz to its board. Abionic SA is a Swiss MedTech company focused on allergy diagnostics. It is developing a portable biomedical device intended to improve or potentially revolutionize the diagnosis of allergies. The article describes the device as portable and biomedical but provides no technical or commercialization details. Abionic recently closed a CHF 2 million first financing round. That financing signals external venture backing from multiple Swiss investors. No operating metrics, revenues, users, or founding year are provided in the article.